Figure 5: Nature Communications

Fig. 5

From: Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Fig. 5

Zymogen factor X-C corrects thrombin generation in plasma spiked with apixaban. a, b Thrombin generation (TG) was measured for 30 min at 37 °C in FX-depleted plasma supplemented with 1 U ml−1 FX-C (15 μg ml−1) in the absence (open symbols) or presence of 2 or 6 μM apixaban (a, APX, blue symbols) or 0.6 or 2 μM edoxaban (b, EDX, orange symbols) with 2 pM tissue factor (TF) and 20 μM PCPS. Thrombin generation was initiated with CaCl2 and a thrombin fluorogenic substrate as detailed in ‘Methods’. The TG profiles of FX-depleted plasma supplemented with 1 U ml−1 (7 μg ml−1) wt-FX in the absence (light gray area under the curve) or presence (dark gray area under the curve) of 2 µM apixaban (a) or 0.6 µM edoxaban (b) are shown. c, d Thrombin generation was measured for 30 min at 37 °C in normal pooled plasma in the presence of 2 pM (c) or 6 pM (d) TF, supplemented with increasing concentrations FX-C (5–40 µg ml−1), 2 μM apixaban, and 20 μM PCPS. The TG profiles of normal pooled plasma in the absence (light gray area under the curve) or presence (dark gray area under the curve) of 2 µM apixaban are shown. All curves are representatives of three to six independent experiments